Do analysts prefer CERO or ATXI?

CERo Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, CERO or ATXI?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CERo Therapeutics N/A N/A -$8.30M -$9.84 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A

Is CERO or ATXI more profitable?

CERo Therapeutics' return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts recommend CERO or ASLN?

CERo Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe CERo Therapeutics is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CERO or ASLN more profitable?

CERo Therapeutics' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts prefer NMTR or CERO?

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than 9 Meters Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better valuation & earnings, NMTR or CERO?

CERo Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 9 Meters Biopharma N/A N/A -$43.77M -$3.46 N/A CERo Therapeutics N/A N/A -$8.30M -$9.84 N/A

Is NMTR or CERO more profitable?

CERo Therapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets 9 Meters Biopharma N/A -584.97% -159.45% CERo Therapeutics N/A N/A -209.40%

Do analysts rate EVFM or CERO?

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Evofem Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media refer more to EVFM or CERO?

In the previous week, CERo Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for CERo Therapeutics and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.67 beat CERo Therapeutics' score of 0.05 indicating that Evofem Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evofem Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CERo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CERO or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% PainReform N/A N/A N/A

Does the media refer more to CERO or PRFX?

In the previous week, CERo Therapeutics had 1 more articles in the media than PainReform. MarketBeat recorded 2 mentions for CERo Therapeutics and 1 mentions for PainReform. CERo Therapeutics' average media sentiment score of 0.05 beat PainReform's score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CERo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral PainReform 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CERo Therapeutics (CERO) Competitors

$0.01 +0.00 (+3.77%)

As of 09/4/2026 03:53 PM Eastern

Compare

CERO vs. ATXI, ASLN, NMTR, EVFM, and PRFX

Should you buy CERo Therapeutics stock or one of its competitors? CERo Therapeutics's main competitors and comparable companies include Avenue Therapeutics (ATXI), ASLAN Pharmaceuticals (ASLN), 9 Meters Biopharma (NMTR), Evofem Biosciences (EVFM), and PainReform (PRFX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CERo Therapeutics compare to Avenue Therapeutics?

CERo Therapeutics (NASDAQ:CERO) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A

CERo Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CERo Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market.

CERo Therapeutics' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Avenue Therapeutics	N/A	-471.57%	-296.50%

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, CERo Therapeutics had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for CERo Therapeutics and 0 mentions for Avenue Therapeutics. CERo Therapeutics' average media sentiment score of 0.05 beat Avenue Therapeutics' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Avenue Therapeutics	Neutral

Summary

CERo Therapeutics beats Avenue Therapeutics on 9 of the 12 factors compared between the two stocks.

How does CERo Therapeutics compare to ASLAN Pharmaceuticals?

CERo Therapeutics (NASDAQ:CERO) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

CERo Therapeutics has higher earnings, but lower revenue than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

In the previous week, CERo Therapeutics had 2 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for CERo Therapeutics and 0 mentions for ASLAN Pharmaceuticals. CERo Therapeutics' average media sentiment score of 0.05 beat ASLAN Pharmaceuticals' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CERo Therapeutics	Neutral
ASLAN Pharmaceuticals	Neutral

CERo Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe CERo Therapeutics is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CERo Therapeutics' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CERo Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Summary

CERo Therapeutics beats ASLAN Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does CERo Therapeutics compare to 9 Meters Biopharma?

9 Meters Biopharma (NASDAQ:NMTR) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

CERo Therapeutics' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
9 Meters Biopharma	N/A	-584.97%	-159.45%
CERo Therapeutics	N/A	N/A	-209.40%

9 Meters Biopharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CERo Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

In the previous week, CERo Therapeutics had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for CERo Therapeutics and 0 mentions for 9 Meters Biopharma. CERo Therapeutics' average media sentiment score of 0.05 beat 9 Meters Biopharma's score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
9 Meters Biopharma	Neutral
CERo Therapeutics	Neutral

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than 9 Meters Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

CERo Therapeutics beats 9 Meters Biopharma on 7 of the 12 factors compared between the two stocks.

How does CERo Therapeutics compare to Evofem Biosciences?

Evofem Biosciences (NASDAQ:EVFM) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Evofem Biosciences has higher revenue and earnings than CERo Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

CERo Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. CERo Therapeutics' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
CERo Therapeutics	N/A	N/A	-209.40%

In the previous week, CERo Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for CERo Therapeutics and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.67 beat CERo Therapeutics' score of 0.05 indicating that Evofem Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evofem Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CERo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Evofem Biosciences has a beta of -1.31, suggesting that its stock price is 231% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Summary

CERo Therapeutics beats Evofem Biosciences on 9 of the 14 factors compared between the two stocks.

How does CERo Therapeutics compare to PainReform?

CERo Therapeutics (NASDAQ:CERO) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CERo Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, PainReform has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

PainReform has higher revenue and earnings than CERo Therapeutics. PainReform is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
PainReform	$31K	27.14	-$5.02M	-$736.66	N/A

CERo Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CERo Therapeutics is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
PainReform	N/A	N/A	N/A

In the previous week, CERo Therapeutics had 1 more articles in the media than PainReform. MarketBeat recorded 2 mentions for CERo Therapeutics and 1 mentions for PainReform. CERo Therapeutics' average media sentiment score of 0.05 beat PainReform's score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CERo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
PainReform	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CERo Therapeutics and PainReform tied by winning 6 of the 12 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERO vs. The Competition

Export

Metric	CERo Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$788K	$12.27B	$7.26B	$12.90B
Dividend Yield	N/A	2.59%	2.53%	8.90%
P/E Ratio	0.00	792.20	273.83	25.45
Price / Sales	N/A	790.22	644.40	92.77
Price / Cash	N/A	92.18	77.39	52.28
Price / Book	0.00	12.47	12.85	6.17
Net Income	-$8.30M	$2.83B	$3.49B	$350.08M
7 Day Performance	N/A	4.03%	1.04%	-0.14%
1 Month Performance	N/A	6.29%	5.52%	1.02%
1 Year Performance	N/A	9.93%	24.39%	14.51%

CERo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERO CERo Therapeutics	1.4203 of 5 stars	$0.01 +3.8%	$30.00 +272,627.3%	-99.8%	$788K	N/A	N/A	8	Gap Up
ATXI Avenue Therapeutics	N/A	$0.41 +59.2%	N/A	-16.2%	$1.35M	N/A	0.02	4	High Trading Volume
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30
NMTR 9 Meters Biopharma	N/A	N/A	N/A	N/A	$1.04M	N/A	N/A	20
EVFM Evofem Biosciences	N/A	$0.01 +1.4%	N/A	-18.1%	$941K	$11.39M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CERo Therapeutics (CERO) Competitors

CERO vs. ATXI, ASLN, NMTR, EVFM, and PRFX

How does CERo Therapeutics compare to Avenue Therapeutics?

Summary

How does CERo Therapeutics compare to ASLAN Pharmaceuticals?

Summary

How does CERo Therapeutics compare to 9 Meters Biopharma?

Summary

How does CERo Therapeutics compare to Evofem Biosciences?

Summary

How does CERo Therapeutics compare to PainReform?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CERo Therapeutics (CERO) Competitors

CERO vs. ATXI, ASLN, NMTR, EVFM, and PRFX

How does CERo Therapeutics compare to Avenue Therapeutics?

Which has higher valuation and earnings, CERO or ATXI?

Do analysts prefer CERO or ATXI?

Which has more volatility and risk, CERO or ATXI?

Is CERO or ATXI more profitable?

Do insiders and institutionals hold more shares of CERO or ATXI?

Does the media favor CERO or ATXI?

Summary

How does CERo Therapeutics compare to ASLAN Pharmaceuticals?

Which has higher valuation and earnings, CERO or ASLN?

Does the media refer more to CERO or ASLN?

Do analysts recommend CERO or ASLN?

Is CERO or ASLN more profitable?

Do insiders and institutionals hold more shares of CERO or ASLN?

Which has more risk & volatility, CERO or ASLN?

Summary

How does CERo Therapeutics compare to 9 Meters Biopharma?

Is NMTR or CERO more profitable?

Which has more volatility and risk, NMTR or CERO?

Do institutionals and insiders hold more shares of NMTR or CERO?

Which has better valuation & earnings, NMTR or CERO?

Does the media refer more to NMTR or CERO?

Do analysts prefer NMTR or CERO?

Summary

How does CERo Therapeutics compare to Evofem Biosciences?

Which has higher valuation & earnings, EVFM or CERO?

Do insiders & institutionals have more ownership in EVFM or CERO?

Do analysts rate EVFM or CERO?

Is EVFM or CERO more profitable?

Does the media refer more to EVFM or CERO?

Which has more volatility and risk, EVFM or CERO?

Summary

How does CERo Therapeutics compare to PainReform?

Do insiders & institutionals have more ownership in CERO or PRFX?

Which has more risk & volatility, CERO or PRFX?

Which has preferable valuation & earnings, CERO or PRFX?

Do analysts prefer CERO or PRFX?

Is CERO or PRFX more profitable?

Does the media refer more to CERO or PRFX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools